This article summarises a recent Auckland case-study presentation by Melbourne oncologist Belinda Yeo on managing complex hormone receptor-positive (HR+)/HER2-negative (HER2–) advanced breast cancer, including the integration of ribociclib (KISQALI®) therapy alongside evidence-based and patient-centred care.
Please login below to download this issue (PDF)